EVEREST-1, NCT05736731: A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression |
|
|
| Active, not recruiting | 1/2 | 160 | US | A2B530, Tmod CAR T-cell Therapy, xT-Onco with HLA-LOH Assay | A2 Biotherapeutics Inc., Tempus AI | Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer | 12/26 | 12/26 | | |
EVEREST-2, NCT06051695: A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression |
|
|
| Recruiting | 1/2 | 474 | US | A2B694, Tmod CAR T-cell Therapy, A2B543, xT CDx with HLA-LOH Assay | A2 Biotherapeutics Inc., Tempus AI | Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM | 06/28 | 06/29 | | |
